Developing and validating a risk prediction model for acute care based on frailty syndromes.

BMJ Open

NIHR CLAHRC Northwest London, Imperial College London, Chelsea and Westminster Campus, London, UK.

Published: October 2015

Objectives: Population ageing may result in increased comorbidity, functional dependence and poor quality of life. Mechanisms and pathophysiology underlying frailty have not been fully elucidated, thus absolute consensus on an operational definition for frailty is lacking. Frailty scores in the acute medical care setting have poor predictive power for clinically relevant outcomes. We explore the utility of frailty syndromes (as recommended by national guidelines) as a risk prediction model for the elderly in the acute care setting.

Setting: English Secondary Care emergency admissions to National Health Service (NHS) acute providers.

Participants: There were N=2,099,252 patients over 65 years with emergency admission to NHS acute providers from 01/01/2012 to 31/12/2012 included in the analysis.

Primary And Secondary Outcome Measures: Outcomes investigated include inpatient mortality, 30-day emergency readmission and institutionalisation. We used pseudorandom numbers to split patients into train (60%) and test (40%). Receiver operator characteristic (ROC) curves and ordering the patients by deciles of predicted risk was used to assess model performance. Using English Hospital Episode Statistics (HES) data, we built multivariable logistic regression models with independent variables based on frailty syndromes (10th revision International Statistical Classification of Diseases, Injuries and Causes of Death (ICD-10) coding), demographics and previous hospital utilisation. Patients included were those>65 years with emergency admission to acute provider in England (2012).

Results: Frailty syndrome models exhibited ROC scores of 0.624-0.659 for inpatient mortality, 0.63-0.654 for institutionalisation and 0.57-0.63 for 30-day emergency readmission.

Conclusions: Frailty syndromes are a valid predictor of outcomes relevant to acute care. The models predictive power is in keeping with other scores in the literature, but is a simple, clinically relevant and potentially more acceptable measurement for use in the acute care setting. Predictive powers of the score are not sufficient for clinical use.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621379PMC
http://dx.doi.org/10.1136/bmjopen-2015-008457DOI Listing

Publication Analysis

Top Keywords

acute care
16
frailty syndromes
16
risk prediction
8
prediction model
8
acute
8
frailty
8
based frailty
8
care setting
8
predictive power
8
clinically relevant
8

Similar Publications

Background: Medication nonadherence remains a significant challenge in the management of chronic conditions, often leading to suboptimal treatment outcomes and increased health care costs. Innovative interventions that address the underlying factors contributing to nonadherence are needed. Gamified mobile apps have shown promise in promoting behavior change and engagement.

View Article and Find Full Text PDF

Background: Whether a detected virus or bacteria is a pathogen that may require treatment, or is merely a commensal 'passenger', remains confusing for many infections. This confusion is likely to increase with the wider use of multi-pathogen PCR.

Objectives: To propose a new statistical procedure to analyse and present data from case-control studies clarifying the probability of causality.

View Article and Find Full Text PDF

ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.

Cytotherapy

January 2025

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.

View Article and Find Full Text PDF

Persistent COVID-19 symptoms and associated factors in a tertiary hospital in Thailand.

J Infect Dev Ctries

December 2024

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand.

Introduction: Coronavirus disease 2019 (COVID-19) is associated with long-term symptoms, but the spectrum of these symptoms remains unclear. We aimed to identify the prevalence and factors associated with persistent symptoms in patients at the post-COVID-19 outpatient clinic.

Methodology: This cross-sectional, observational study included hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients followed-up at a post-COVID-19 clinic between September 2021 and January 2022.

View Article and Find Full Text PDF

Experiences of patients who retest positive for SARS-CoV-2 Omicron variant after discharge: a qualitative study.

J Infect Dev Ctries

December 2024

The Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Prevention Research Institute, Shandong Cancer Hospital), Jinan 250117, China.

Introduction: In this study, we analyzed the psychological aspects of coronavirus disease 2019 (COVID-19) patients who were discharged from the hospitals in Shanghai, China, and later had positive nucleic acid retest results for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infection (re-positive COVID-19). The purpose was to gain clarity on the patients' needs and to provide evidence for the medical staff to deliver scientific and targeted health care to the patients.

Methodology: We screened patients who tested positive for SARS-CoV-2 Omicron variant infection by nucleic acid testing after having previously recovered from a COVID-19 infection and being discharged from Shanghai shelter hospitals or COVID-19-designated hospitals from April 3, 2022, to May 10, 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!